ParkerVision appoints Lewis Titterton as Class II director

PARKERVISION INC

Effective June 22, 2023, Titterton fills a board vacancy; he previously served from Sept 2018 to Apr 2019.
Titterton is lead independent director at Anixa Biosciences (ANIX) and chaired NYMED's board.
CEO Jeffery Parker praised Titterton's biotech background as relevant to ParkerVision's licensing strategy.
Company entered a standard indemnification agreement with Titterton.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Lewis H. Titterton

Class II director

PRKR · PARKERVISION INC

Effective: 2023-06-22
Filed: June 26, 2023, 7:59 PM ET

Effective June 22, 2023, the Board of Directors of the Company appointed Lewis H. Titterton to fill a Class II director vacancy.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Lewis H. Titterton was appointed as Class II director at PARKERVISION INC.

Action: appointed
Role: Class II director

Exact text from the filing

Effective June 22, 2023, the Board of Directors of the Company appointed Lewis H. Titterton to fill a Class II director vacancy.

View on SEC.gov

PARKERVISION INC filing history →

Source: SEC EDGAR

accession 0001437749-23-018338

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.